Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Julphar
AstraZeneca
Cantor Fitzgerald
Baxter
Johnson and Johnson
Cerilliant
Daiichi Sankyo
Harvard Business School

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,517,334

« Back to Dashboard

Which drugs does patent 7,517,334 protect, and when does it expire?

Patent 7,517,334 protects FORTEO and is included in one NDA.

This patent has twenty-five patent family members in eighteen countries.
Summary for Patent: 7,517,334
Title:Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
Abstract: A medication dispensing apparatus with a spring-driven locking feature includes a drive member movable in a distal direction within a housing, and a fluid container with a piston that is advanceable by the drive member (60) when such drive member is moved distally by a driving means. The apparatus includes a latching element (180) having a skid (190) that is slidable along a surface of the drive member as the drive member passes distally during advancement. The drive member is arranged with the skid so as to maintain a latching lip of the latching element against a spring force in a first position free of the driving means during dose preparing and injecting prior to a final dose administration. The skid-engaging surface shifts distally of the skid such that the skid passes beyond a proximal end of that surface upon administration of a final dose, whereby the latching lip is urged by the spring force from the first position to a second position to physically lock the driving means to prevent further dose preparing and injecting.
Inventor(s): Jacobs; Alexander Thomas (Cambridge, MA), Judson; Jared Alden (Topsfield, MA), Row; Gordon Davidson (Groton, MA)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:10/598,987
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,517,334
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 7,517,334

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,517,334

PCT Information
PCT FiledMarch 25, 2005PCT Application Number:PCT/US2005/010206
PCT Publication Date:October 20, 2005PCT Publication Number: WO2005/097233

Non-Orange Book US Patents Family Members for Patent 7,517,334

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,857,791 Medication dispensing apparatus with gear set having drive member accommodating opening ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
Federal Trade Commission
UBS
Harvard Business School
Chubb
AstraZeneca
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.